Kalcipos-D forte 500mg/800 IU chewable tablets

  • Name:

    Kalcipos-D forte 500mg/800 IU chewable tablets

  • Company:
    info
  • Active Ingredients:

    Calcium Carbonate, Vitamin D3

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/10/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/10/2020

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
Medicine Name Dona 500mg Capsules Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 96 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 October 2020

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Updated on 20 October 2020 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 13 August 2019 PIL

Reasons for updating

  • Change to product name

Updated on 8 November 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 November 2018

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Updated on 16 July 2018

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: Indication – adults over 18 years

In section 4.3: Severe renal impairment added, Hypercalciuria and hypercalcaemia and diseases and/or conditions resulting in which lead to hypercalcaemia or hypercalciuria added

In section 4.4: Information regarding milk-alkali syndrome added

In section 4.6: Information regarding pregnancy added

In section 4.8: Full adverse reaction definitions added

In section 5.1: Information regarding pharmacotherapeutic group added

In section 5.2: Information regarding absorption, distribution added

In section 10: Date of revision changed.

 

Updated on 11 January 2016

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 January 2016 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: there is a slight text change

In section 4,2: Restructuring to this section has been undertaken

In section 4.3: Reference to use in children has been removed from this section

In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.

In section 4.7: Warning in relation to driving and use of machinery has been added

In section 4.8: Information regarding patients with renal impairment has been added

In In section 10: The date of revision has been changed.

Updated on 11 January 2016 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: there is a slight text change

In section 4,2: Restructuring to this section has been undertaken

In section 4.3: Reference to use in children has been removed from this section

In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.

In section 4.7: Warning in relation to driving and use of machinery has been added

In section 4.8: Information regarding patients with renal impairment has been added

In In section 10: The date of revision has been changed.

Updated on 1 December 2015 SPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 3: A slight amendment has been made to the description of the pharmaceutical form

In section 4.4: Very minor typo correct

In section 4.8: adverse reaction reporting statement has been added

In section 5.2: slight correction made to two sub-headings

In section 6.4: Reference to in-use has been added

In section 9: date of last renewal has been added

In section 10: The date of revision has been changed.

Updated on 1 December 2015 PIL

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 3: A slight amendment has been made to the description of the pharmaceutical form

In section 4.4: Very minor typo correct

In section 4.8: adverse reaction reporting statement has been added

In section 5.2: slight correction made to two sub-headings

In section 6.4: Reference to in-use has been added

In section 9: date of last renewal has been added

In section 10: The date of revision has been changed.

Updated on 10 October 2013 PIL

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 5.1: Additional information has been added to this section outlining the results of a clinical study

In section 10: The date of revision has been changed.

Updated on 10 October 2013 SPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 5.1: Additional information has been added to this section outlining the results of a clinical study

In section 10: The date of revision has been changed.

Updated on 27 November 2012 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

In section 4.4; A correction has been made regarding the content of sucrose

Updated on 27 November 2012 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4; A correction has been made regarding the content of sucrose

Updated on 13 November 2012 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Free text change information supplied by the pharmaceutical company

In section 4.4: a correction has been made to the sucrose content. it was incorrectly stated to be 3.8mg and this has now been corrected to 1.8mg
In section 6.1: the list of excipients has been amended

Updated on 13 November 2012 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4: a correction has been made to the sucrose content. it was incorrectly stated to be 3.8mg and this has now been corrected to 1.8mg
In section 6.1: the list of excipients has been amended

Updated on 7 November 2012 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: text regarding the excipients has been changed

In section 3: additional information regarding the descriptions of the tablet has changed

In section 4.3: text has changed regarding the contraindications

In section 4.5: Additional warning regarding the administration of strontium and calcium has been added.

In section 4.6: additional information regarding fertility has been added

In section 4.8: small correction made to the frequencies

In section 6.3: additional information regarding the in-shelf life use has been added

In section 6.5; the word chewable has been added

In section 10: the revision date has changed

Updated on 7 November 2012 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: text regarding the excipients has been changed

In section 3: additional information regarding the descriptions of the tablet has changed

In section 4.3: text has changed regarding the contraindications

In section 4.5: Additional warning regarding the administration of strontium and calcium has been added.

In section 4.6: additional information regarding fertility has been added

In section 4.8: small correction made to the frequencies

In section 6.3: additional information regarding the in-shelf life use has been added

In section 6.5; the word chewable has been added

In section 10: the revision date has changed

Updated on 21 September 2012 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: information regarding the excipients has been removed

In section 4.3: Information regarding hydrogenated soya oil has been removed

In section 4.4: a correction has been made to the quantitative composition of sucrose

In section 6.1: the excipient list has changed

In section 10: the revision date has changed

Updated on 21 September 2012 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: information regarding the excipients has been removed

In section 4.3: Information regarding hydrogenated soya oil has been removed

In section 4.4: a correction has been made to the quantitative composition of sucrose

In section 6.1: the excipient list has changed

In section 10: the revision date has changed

Updated on 29 February 2012 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 29 February 2012 PIL

Reasons for updating

  • New SPC for medicines.ie

Free text change information supplied by the pharmaceutical company

None provided